Compass Therapeutics, Inc. (CMPX)

Over the past six months, Compass Therapeutics, Inc. stock has experienced significant positive movement, with a return of +109.8%. As of January 30, 2026, the company's market capitalization was $1.14 billion, showing a 19.18% increase over the last 12 months, despite a -5.31% decrease in the past 30 days. Recent events include analyst coverage initiations with positive recommendations, corporate updates on clinical trial data, financial performance with increased R&D costs and pipeline challenges, and a proposed public offering in August 2025.

Compass Therapeutics, Inc. does not exhibit traditional demand seasonality for its products and services. The demand for its pipeline candidates is driven by the progression of clinical trials, regulatory approvals, and the medical need for treatments for the diseases they target, rather than seasonal consumer trends.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing antibody-based therapeutics for human diseases. The company's scientific approach centers on the interplay between angiogenesis, the immune system, and tumor growth, targeting multiple critical biological pathways for an effective anti-tumor response. Key product candidates include Tovecimig (CTX-009), CTX-471, CTX-8371, CTX-10726, and VEGF-IO Bispecific / Multiple.

Compass Therapeutics, Inc. is headquartered in Boston, Massachusetts, and focuses on the development of therapeutics in the United States.

Compass Therapeutics generally holds a positive brand reputation among analysts, with a consensus rating of "Buy" or "Moderate Buy". Promising data from colorectal cancer treatments and the positive safety profile of CTX-8371 have been positive influences. However, the failure of dilpacimab in colorectal cancer trials and uncertainties regarding clinical outcomes have presented challenges to its reputation.

Compass Therapeutics, Inc. has 214 institutional owners and shareholders holding a total of 158,259,051 shares. Institutions hold approximately 55.90% to 56.51% of the company's common stock, insiders own about 8.09% to 21.45%, and retail investors hold approximately 64.27%. Carl Gordon is noted as owning the most shares individually.